vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Kennedy-Wilson Holdings, Inc. (KW). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $120.6M, roughly 1.4× Kennedy-Wilson Holdings, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -11.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -6.0%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Kennedy Wilson is a real estate investment company headquartered in Beverly Hills, California, United States.
ESPR vs KW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $120.6M |
| Net Profit | — | $58.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 57.3% |
| Net Margin | — | 48.1% |
| Revenue YoY | 143.7% | -11.0% |
| Net Profit YoY | — | 32.7% |
| EPS (diluted) | $0.32 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $120.6M | ||
| Q3 25 | $87.3M | $116.4M | ||
| Q2 25 | $82.4M | $135.7M | ||
| Q1 25 | $65.0M | $128.3M | ||
| Q4 24 | $69.1M | $135.5M | ||
| Q3 24 | $51.6M | $127.5M | ||
| Q2 24 | $73.8M | $132.0M | ||
| Q1 24 | $137.7M | $136.4M |
| Q4 25 | — | $58.0M | ||
| Q3 25 | $-31.3M | $-10.2M | ||
| Q2 25 | $-12.7M | $5.6M | ||
| Q1 25 | $-40.5M | $-29.6M | ||
| Q4 24 | — | $43.7M | ||
| Q3 24 | $-29.5M | $-66.8M | ||
| Q2 24 | $-61.9M | $-48.3M | ||
| Q1 24 | $61.0M | $37.7M |
| Q4 25 | 50.6% | 57.3% | ||
| Q3 25 | -11.4% | -6.2% | ||
| Q2 25 | 8.6% | 7.4% | ||
| Q1 25 | -34.0% | -26.9% | ||
| Q4 24 | -6.4% | 36.7% | ||
| Q3 24 | -31.0% | -60.8% | ||
| Q2 24 | 3.5% | -45.5% | ||
| Q1 24 | 52.5% | 47.2% |
| Q4 25 | — | 48.1% | ||
| Q3 25 | -35.9% | -8.8% | ||
| Q2 25 | -15.4% | 4.1% | ||
| Q1 25 | -62.2% | -23.1% | ||
| Q4 24 | — | 32.3% | ||
| Q3 24 | -57.2% | -52.4% | ||
| Q2 24 | -83.9% | -36.6% | ||
| Q1 24 | 44.3% | 27.6% |
| Q4 25 | $0.32 | $0.22 | ||
| Q3 25 | $-0.16 | $-0.15 | ||
| Q2 25 | $-0.06 | $-0.05 | ||
| Q1 25 | $-0.21 | $-0.30 | ||
| Q4 24 | $-0.14 | $0.24 | ||
| Q3 24 | $-0.15 | $-0.56 | ||
| Q2 24 | $-0.33 | $-0.43 | ||
| Q1 24 | $0.34 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $184.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.5B |
| Total Assets | $465.9M | $6.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $184.5M | ||
| Q3 25 | $92.4M | $382.6M | ||
| Q2 25 | $86.1M | $309.1M | ||
| Q1 25 | $114.6M | $356.6M | ||
| Q4 24 | $144.8M | $217.5M | ||
| Q3 24 | $144.7M | $367.1M | ||
| Q2 24 | $189.3M | $366.5M | ||
| Q1 24 | $226.6M | $541.9M |
| Q4 25 | $-302.0M | $1.5B | ||
| Q3 25 | $-451.4M | $1.5B | ||
| Q2 25 | $-433.5M | $1.6B | ||
| Q1 25 | $-426.2M | $1.6B | ||
| Q4 24 | $-388.7M | $1.6B | ||
| Q3 24 | $-370.2M | $1.6B | ||
| Q2 24 | $-344.2M | $1.7B | ||
| Q1 24 | $-294.3M | $1.7B |
| Q4 25 | $465.9M | $6.6B | ||
| Q3 25 | $364.0M | $6.7B | ||
| Q2 25 | $347.1M | $6.8B | ||
| Q1 25 | $324.0M | $7.2B | ||
| Q4 24 | $343.8M | $7.0B | ||
| Q3 24 | $314.1M | $7.4B | ||
| Q2 24 | $352.3M | $7.5B | ||
| Q1 24 | $373.1M | $7.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $11.4M |
| Free Cash FlowOCF − Capex | — | $-55.2M |
| FCF MarginFCF / Revenue | — | -45.8% |
| Capex IntensityCapex / Revenue | 0.0% | 55.2% |
| Cash ConversionOCF / Net Profit | — | 0.20× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-103.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $11.4M | ||
| Q3 25 | $-4.3M | $-7.6M | ||
| Q2 25 | $-31.4M | $42.0M | ||
| Q1 25 | $-22.6M | $-51.9M | ||
| Q4 24 | $-35.0M | $55.1M | ||
| Q3 24 | $-35.3M | $-5.6M | ||
| Q2 24 | $-7.2M | $36.7M | ||
| Q1 24 | $53.8M | $-5.6M |
| Q4 25 | — | $-55.2M | ||
| Q3 25 | — | $-18.0M | ||
| Q2 25 | — | $29.4M | ||
| Q1 25 | — | $-59.7M | ||
| Q4 24 | — | $-76.5M | ||
| Q3 24 | $-35.5M | $-27.7M | ||
| Q2 24 | $-7.3M | $-500.0K | ||
| Q1 24 | $53.8M | $-57.1M |
| Q4 25 | — | -45.8% | ||
| Q3 25 | — | -15.5% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | -46.5% | ||
| Q4 24 | — | -56.5% | ||
| Q3 24 | -68.7% | -21.7% | ||
| Q2 24 | -9.9% | -0.4% | ||
| Q1 24 | 39.0% | -41.9% |
| Q4 25 | 0.0% | 55.2% | ||
| Q3 25 | 0.0% | 8.9% | ||
| Q2 25 | 0.0% | 9.3% | ||
| Q1 25 | 0.0% | 6.1% | ||
| Q4 24 | 0.0% | 97.1% | ||
| Q3 24 | 0.3% | 17.3% | ||
| Q2 24 | 0.1% | 28.2% | ||
| Q1 24 | 0.1% | 37.8% |
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 7.50× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | -0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
KW
| Consolidated Portfolio Segment | $84.9M | 70% |
| Investment Management Fees | $30.4M | 25% |
| Real Estate | $5.1M | 4% |
